当前位置：药药网 / 医药文献 /临床试验研究设计终点和生物标志物药物安全性(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于等于0,小于611)：
临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
cytogenetics for diagnosis and prediction,307–308,314–315
307 308 314 315
Chronic myeloid leukemia (CML)clinical features,293–294
293 294
cytogenetics for diagnosis and prediction,304–305
304 305
toxicity as basis for exclusion,74–76
74 76
Expanded Disability Status Scale (EDSS),360–361,406–407
360 361 406 407
Atherosclerosis C-reactive protein as biomarker,349–351
349 351
5-Aza-deoxycytidine myelodysplastic syndrome management,299
299
Bacillus Calmette-Guerin (BCG),490
490
Baker v. St. Agnes Hospital,569
569
BCR-ABL see Philadelphia chromosome Bedikian study,234–235
234 235
Berthold study,148–149
148 149
Biomarkers breast cancer,332–337
332 337
C-reactive protein see C-reactive protein circulating tumor cells,338
338
colorectal cancer,337–340
337 340
DNA microarray colon cancer,343–344
343 344
hepatocellular carcinoma,344–345
344 345
ovarian cancer,342–343
342 343
hepatitis C virus infection,381–382
381 382
mass spectrometry,349
349
measurement relative to chemotherapy,322
322
predictive versus prognostic,328–330
328 330